SCHEMBL23263176

SCHEMBL23263176

O=c1c(O)ccccc1-c1ncccn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP6 P55212 1/20 0.46
CYP19A1 P11511 1/20 0.45
BRD4 O60885 1/20 0.41
PTPRC P08575 2/20 0.39
CTSL P07711 1/20 0.39
CTSS P25774 1/20 0.39
PTPN13 Q12923 1/20 0.39
MAOA P21397 3/20 0.39
KMT2A Q03164 3/20 0.39
MAPT P10636 3/20 0.39
MEN1 O00255 2/20 0.39
TDP2 O95551 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
NSD2 O96028 1/20 0.39
ABL1 P00519 1/20 0.39
PLCG1 P19174 1/20 0.39
CES1 P23141 1/20 0.39
PAX8 Q06710 1/20 0.39
RIN1 Q13671 1/20 0.39
BCL2 P10415 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL679952 0.82 CYP19A1 (0.55) CASP6CYP19A1KMT2AMAPTTDP1
SCHEMBL31551042 0.82 CYP19A1 (0.55) CASP6CYP19A1KMT2AMAPTTDP1
Hydrochloric Acid SCHEMBL15621988 0.80 CYP19A1 (0.53) CASP6CYP19A1KMT2AMAPTTDP1
SCHEMBL27654823 0.80 CYP19A1 (0.53) CASP6CYP19A1KMT2AMAPTTDP1
SCHEMBL27018672 0.75 BRD4 (0.44) BRD4PTPRCCTSLCTSSPTPN13
SCHEMBL10599951 0.74 KDM4E (0.45) CASP6BRD4PTPRCCTSLCTSS
SCHEMBL28348282 0.72 MAOA (0.45) CASP6CYP19A1MAOAKMT2AMAPT
SCHEMBL29889975 0.72 CASP6 (0.41) CASP6CYP19A1MAOAMAPTSMN1; SMN2
SCHEMBL23263132 0.72 CASP6 (0.41) CASP6CYP19A1MAOAMAPTSMN1; SMN2
SCHEMBL12853990 0.71 PTPRC (0.44) CASP6BRD4PTPRCCTSLCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024073131-A2 METHOD OF TREATING NEURODEGENERATIVE DISEASES THE BOARD OF TRUSTEES OF THE UNIVESITY OF ILLINOIS (US) 2024-04-04 WO disclosed
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 US disclosed
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS KINESID THERAPEUTICS, INC. (US) 2024-01-18 US disclosed
WO-2021076945-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS Ambys Medicines, Inc. (US) 2021-04-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018105-A1 TROPOLONE DERIVATIVES AND TAUTOMERS THEREOF FOR IRON REGULATION IN ANIMALS TXNRD2, TXNRD1, SDHB CASP6 4029/4885CYP19A1 213/4885BRD4 4625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.